Portrazza market seen growing on lung cancer demand and personalized therapy trends

The Business Research Company says the Portrazza market is set for steady growth through 2035 as lung cancer cases rise, healthcare spending increases and targeted oncology therapies gain ground. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - Rising lung cancer incidence is expanding demand for Portrazza, a targeted biologic used in non-small cell lung cancer. - The market is also being shaped by broader shifts toward precision oncology, combination regimens and personalized cancer care. - Growing healthcare spending can improve access to advanced therapies and support continued development of targeted cancer drugs.

What happened: - The Business Research Company published its "Portrazza Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035." - The report says the Portrazza market is gaining momentum as cancer treatment advances and targeted therapies become more widely used. - The report includes sample access and the full market report through the company's website: Download a free sample and View the full report.

The details: - Portrazza contains necitumumab, a monoclonal antibody designed to treat non-small cell lung cancer. - The drug targets epidermal growth factor receptor, or EGFR, to slow tumor progression and support use with chemotherapy in NSCLC patients. - Historical market growth was driven by higher NSCLC prevalence, progress in monoclonal antibodies, expanded oncology clinical infrastructure, wider use of targeted cancer drugs and improved screening rates. - Forecast growth is expected to come from stronger demand for precision oncology therapies, more investment in biologic cancer drugs, broader pipelines for EGFR-targeted treatments, wider adoption of combination regimens and more personalized lung cancer management. - Forecast-period trends include increased use of EGFR-targeted monoclonal antibodies, deeper integration into lung cancer protocols, more focus on targeted oncology biologics, growth in combination therapy strategies and stronger emphasis on personalized cancer care. - Lung cancer cases are rising because of smoking, environmental pollutants, genetic predisposition and occupational exposures such as asbestos. - American Cancer Society Facts and Figures showed new U.S. lung and bronchus cancer cases rising from 236,740 in 2022 to 238,340 in 2023. - UK healthcare expenditure reached about US$414 billion, or £317 billion, in 2024, with nominal growth of 6.5% from 2023, according to the Office for National Statistics. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - Portrazza sits at the intersection of two larger market forces: higher cancer burden and more selective treatment based on biomarkers. - The report's emphasis on EGFR-targeted therapy suggests competition in lung cancer is shifting toward biologics that can fit into more tailored treatment plans. - The market outlook implies that access, reimbursement and oncology infrastructure will matter as much as the drug's clinical profile.

What's next: - North America held the largest Portrazza market share in 2025. - Asia-Pacific is projected to be the fastest-growing region over the forecast period. - The report covers Asia-Pacific, Western and Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report series adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and trend analysis. - The company listed contacts for follow-up, including Saumya Sahay and Oliver Guirdham, along with regional phone numbers and email support.

The bottom line: - Portrazza's growth story is tied to the broader move toward targeted lung cancer care, with regional expansion likely strongest where oncology spending and precision medicine adoption are rising.